Treatment Outcome after Fractionated Conformal Radiotherapy for Hepatocellular Carcinoma in Patients with Child-Pugh Classification B in Korea (KROG 16-05)
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose There is limited data on radiotherapy (RT) for hepatocellular carcinoma (HCC) in patients with Child-Pugh classification B (CP-B). This study aimed to evaluate the treatment outcomes of fractionated conformal RT in HCC patients with CP-B. Materials and Methods We retrospectively reviewed the data of HCC patients with CP-B treated with RT between 2009 and 2014 at 13 institutions in Korea. HCC was diagnosed by the Korea guideline of 2009, and modern RT techniques were applied. Fraction size was 5 Gy and the biologically effective dose (BED) 40 Gy10 (/=10 Gy). A total of 184 patients were included in this study. Results Initial CP score was seven in 62.0% of patients, eight in 31.0%, and nine in 7.0%. Portal vein tumor thrombosis was present in 66.3% of patients. The BED ranged from 40.4 to 89.6 Gy10 (median, 56.0 Gy10). After RT completion, 48.4% of patients underwent additional treatment. The median overall survival (OS) was 9.4 months. The local progression-free survival and OS rates at 1 year were 58.9% and 39.8%, respectively. In the multivariate analysis, non-classic radiation-induced liver disease (RILD) (p < 0.001) and additional treatment (p < 0.001) were the most significant prognostic factors of OS. Among 132 evaluable patients without progressive disease, 19.7% experienced non-classic RILD. Normal liver volume was the most predictive dosimetric parameter of non-classic RILD. Conclusion Fractionated conformal RT showed favorable OS with a moderate risk non-classic RILD. The individual radiotherapy for CP-B could be cautiously applied weighing the survival benefits and the RILD risks.
Abstract
Purpose There is limited data on radiotherapy (RT) for hepatocellular carcinoma (HCC) in patients with Child-Pugh classification B (CP-B). This study aimed to evaluate the treatment outcomes of fractionated conformal RT in HCC patients with CP-B. Materials and Methods We retrospectively reviewed the data of HCC patients with CP-B treated with RT between 2009 and 2014 at 13 institutions in Korea. HCC was diagnosed by the Korea guideline of 2009, and modern RT techniques were applied. Fraction size was 5 Gy and the biologically effective dose (BED) 40 Gy10 (/=10 Gy). A total of 184 patients were included in this study. Results Initial CP score was seven in 62.0% of patients, eight in 31.0%, and nine in 7.0%. Portal vein tumor thrombosis was present in 66.3% of patients. The BED ranged from 40.4 to 89.6 Gy10 (median, 56.0 Gy10). After RT completion, 48.4% of patients underwent additional treatment. The median overall survival (OS) was 9.4 months. The local progression-free survival and OS rates at 1 year were 58.9% and 39.8%, respectively. In the multivariate analysis, non-classic radiation-induced liver disease (RILD) (p < 0.001) and additional treatment (p < 0.001) were the most significant prognostic factors of OS. Among 132 evaluable patients without progressive disease, 19.7% experienced non-classic RILD. Normal liver volume was the most predictive dosimetric parameter of non-classic RILD. Conclusion Fractionated conformal RT showed favorable OS with a moderate risk non-classic RILD. The individual radiotherapy for CP-B could be cautiously applied weighing the survival benefits and the RILD risks.
참고문헌 (29)
- Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
- European Association for the Study of the Liver, "EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma", J Hepatol, 56, pp.908~943 (2012)
- Pinter M, "Cancer and liver cirrhosis: implications on prognosis and management", ESMO Open, 1, pp.e000042~ (2016)
- Granito A, "Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis", Lancet Oncol, 18, pp.e101~e112 (2017)
- Emami B, "Tolerance of normal tissue to therapeutic irradiation", Int J Radiat Oncol Biol Phys, 21, pp.109~122 (1991)
- Feng M, "Radiation therapy for hepatocellular carcinoma", Semin Radiat Oncol, 21, pp.271~277 (2011)
- Pan CC, "Radiation-associated liver injury", Int J Radiat Oncol Biol Phys, 76(3 Suppl), pp.S94~S100 (2010)
- Guha C, "Hepatic radiation toxicity : avoidance and amelioration", Semin Radiat Oncol, 21, pp.256~263 (2011)
- Chino F, "The role of external beam radiotherapy in the treatment of hepatocellular cancer", Cancer, 124, pp.3476~3489 (2018)
- Culleton S, "Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma", Radiother Oncol, 111, pp.412~417 (2014)
- Korean Liver Cancer Study Group, "Practice guidelines for management of hepatocellular carcinoma 2009", Korean J Hepatol, 15, pp.391~423 (2009)
- Son SH, "Determination of the α", β ratio for the normal liver on the basis of radiation-induced hepatic toxicities in patients with hepatocellular carcinoma, 2013, pp.8, 61~
- 임채홍, "Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines", Radiation oncology journal, 34(3), pp.160~167 (2016), 대한방사선종양학회
- Lock MI, "Strategies to tackle the challenges of external beam radiotherapy for liver tumors", World J Hepatol, 9, pp.645~656 (2017)
- Nabavizadeh N, "Safety and efficacy of accelerated hypofractionation and stereotactic body radiation therapy for hepatocellular carcinoma patients with varying degrees of hepatic impairment", Int J Radiat Oncol Biol Phys, 100, pp.577~585 (2018)
- Nitin Ohri, "Local Control After Stereotactic Body Radiation Therapy for Liver Tumors", International Journal of Radiation Oncology*Biology*Physics (2018), Elsevier BV[DOI]
- 차혜정, "Clinical Practice Patterns of Radiotherapy in Patients with Hepatocellular Carcinoma: A Korean Radiation Oncology Group Study (KROG 14-07)", Cancer Research and Treatment, 49(1), pp.61~69 (2017), 대한암학회
- Bae SH, "Practical patterns for stereotactic body radiotherapy to hepatocellular carcinoma in Korea : a survey of the Korean Stereotactic Radiosurgery Group", Jpn J Clin Oncol, 46, pp.363~369 (2016)
- Liang SX, "Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma", Cancer, 103, pp.2181~2188 (2005)
- Mornex F, "Feasibility and efficacy of high-dose three-dimensionalconformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies : mature results of the French Phase II RTF-1 trial", Int J Radiat Oncol Biol Phys, 66, pp.1152~1158 (2006)
- Milano MT, "Normal tissue toxicity after small field hypofractionated stereotactic body radiation", Radiat Oncol, 3, pp.36~ (2008)
- Velec M, "Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 97, pp.939~946 (2017)
- Dawson LA, "Analysis of radiation-induced liver disease using the Lyman NTCP model", Int J Radiat Oncol Biol Phys, 53, pp.810~821 (2002)
- Cheng JC, "Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease", Int J Radiat Oncol Biol Phys, 60, pp.1502~1509 (2004)
- Dawson LA, "Use of principal component analysis to evaluate the partial organ tolerance of normal tissues to radiation", Int J Radiat Oncol Biol Phys, 62, pp.829~837 (2005)
- Kim TH, "Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy", Int J Radiat Oncol Biol Phys, 67, pp.225~231 (2007)
- Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
- Trevisani F, "Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate", advanced cirrhosis?, 2007, pp.102, 2448~2457
- El-Serag HB, "Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States : a population-based study", J Hepatol, 44, pp.158~166 (2006)